Duchenne muscular dystrophy (DMD), the most common inherited muscular dystrophy of childhood, leads to death due to cardiorespiratory failure. Paradoxically, mdx mice with the same genetic deficiency of dystrophin exhibit minimal cardiac dysfunction, impeding the development of therapies. We postulated that the difference between mdx and DMD might result from differences in telomere lengths in mice and humans. We show here that, like DMD patients, mice that lack dystrophin and have shortened telomeres (mdx/mTR KO ) develop severe functional cardiac deficits including ventricular dilation, contractile and conductance dysfunction, and accelerated mortality. These cardiac defects are accompanied by telomere erosion, mitochondrial fragmentation and increased oxidative stress. Treatment with antioxidants significantly retards the onset of cardiac dysfunction and death of mdx/mTR KO mice. In corroboration, all four of the DMD patients analysed had 45% shorter telomeres in their cardiomyocytes relative to age-and sex-matched controls. We propose that the demands of contraction in the absence of dystrophin coupled with increased oxidative stress conspire to accelerate telomere erosion culminating in cardiac failure and death. These findings provide strong support for a link between telomere length and dystrophin deficiency in the etiology of dilated cardiomyopathy in DMD and suggest preventive interventions.
DMD is a lethal X-linked recessive disease that affects 1 in 3,500 live-born boys. DMD is characterized by severe progressive muscle wasting due to mutations in dystrophin, which links the inner cytoskeleton with the extracellular matrix and therefore plays a key role in plasma membrane integrity in both skeletal and cardiac muscles 1, 2 . Loss of dystrophin destabilizes the membrane, which leads to increased muscle fragility and renders muscle cells highly susceptible to contraction-induced injury 3 . Although DMD is diagnosed on the basis of early skeletal muscle symptoms, progressive cardiorespiratory failure is the primary cause of death, generally in the third decade of life [4] [5] [6] [7] . As the specific mechanisms underlying heart failure in DMD patients are poorly understood, present treatments entail supportive heart failure strategies such as administration of angiotensin-converting enzyme inhibitors and β-adrenergic blockers 8,9 . Crucial to our understanding of the molecular mechanisms that underlie the development of DMD and to the design of preventive and therapeutic regimens are animal models that are engineered with tissue-specific mutations that phenocopy the human disease. The most commonly used animal model of DMD is the mdx mouse, in which a nonsense mutation in the dystrophin gene eliminates expression of dystrophin 10 . Despite the absence of dystrophin in skeletal and cardiac muscles of mdx mice 10 , these animals fail to recapitulate the hallmark features of DMD, including severe muscle weakness, progressive cardiomyopathy and shortened lifespan 6, 7, 11, 12 , severely limiting the utility of the model. A mouse model that more closely resembles the human disease would be invaluable, both for elucidating the pathophysiologic mechanism of cardiac failure in DMD and for the development of more efficacious therapies that target the heart.
A major difference between humans and laboratory mice is the length of their telomeres, specialized DNA-protein complexes comprised of tandem G-rich repeats and located at the ends of eukaryotic chromosomes, which serve to cap and protect chromosome ends 13 . For unknown reasons, telomere lengths differ among species, ranging from organs with high rates of proliferation and turnover 16 . By deleting the RNA component TERC (mTR) of telomerase, mTR KO mice have been generated that are characterized by a progressive shortening of telomeres, which occurs in the germ line over successive generations (G1-G6). Indeed, ubiquitous shortening of telomeres by successive inbreeding of telomerase-deficient mice (mTR KO ) reveals defects in a range of both proliferative and low-mitotic tissues, similar to what is seen in ageing humans 16 .
Given the established link between telomere dysfunction and proliferative defects 16 , we previously postulated that deficiency of a single key protein (such as dystrophin) might be unmasked in specific cell types (such as muscle) in mice with a moderately reduced telomere reserve (G1 or G2). We tested this hypothesis by crossing mdx mice with mice lacking the RNA component of telomerase (mdx/mTR KO ). As predicted, telomere shortening depleted the proliferative stem cell reservoir that drives regeneration of damaged dystrophic skeletal muscles and the severe progressive muscle weakness typical of DMD was recapitulated 17 .
Here we show that mdx/mTR KO mice manifest all of the classic signs of dilated cardiomyopathy and heart failure seen in DMD patients. In contrast to skeletal muscle, the heart is a largely quiescent tissue characterized by low cell turnover 18 . It therefore seemed counter-intuitive that a similar mechanism could drive the severe cardiomyopathy seen in DMD. Yet, we found that mdx/mTR KO mice at early generations (G1 and G2) are characterized by severe contractile and conductance dysfunction, ventricular dilation and early death.
A test of the clinical relevance of this model revealed that telomere lengths in cardiomyocytes from four DMD patients are 45% shorter than in cardiomyocytes of age-and sex-matched human controls. Together, these results highlight that in a setting of mild ubiquitous telomere shortening, the absence of a single contractile protein, dystrophin, elicits tissue-specific defects and significant telomere shortening in non-proliferative heart muscles. This leads to a cycle of DNA damage and telomere shortening, which in turn leads to accelerated organ failure due to mitochondrial dysfunction and oxidative stress. This finding led us to test treatments with antioxidants, which as predicted, delayed the progression of dilated cardiomyopathy and the onset of death in mdx/mTR KO mice. Our results provide insights into the cardiorespiratory defects specific to DMD patients and a murine model for testing treatments that will probably impact the quality of life and survival of patients.
RESULTS
We generated dystrophic mice lacking telomerase activity by crossing mTR Het mice (lacking one copy of the RNA component of telomerase, known as mTR or Terc 19 ) with the exon 53 dystrophin mutation known as C57BL6 mdx 4cv (ref. 20; hereafter designated as mdx) as previously described 17 . Rigorous breeding strategies are critical to generate the appropriate controls and consistent phenotypes across generations ( Supplementary Fig. S1a ). Our breeding scheme yields mdx/mTR KO mice with a genetic background identical to control mTR KO mice, which is critical, as telomere length differs among mouse strains 15 . As the human disease is X-linked 21 , our studies were restricted to male mice. Importantly, the cardiac dystrophic phenotype was compared in mice of all genotypes at the same age and generation, as telomere shortening increases in mTR KO mice with successive generations. Double-mutant mice lacking dystrophin and telomerase at the first and second generation (mdx/mTR G1 and mdx/mTR G2 , hereafter designated as G1 or G2, respectively) were compared with controls of the same generations: C57BL6 wild-type mice (WT), heterozygous mice mdx/mTR Het (Het; lacking dystrophin completely-hence mdx-and expressing one allele encoding TERC), and homozygous TERC-null mice (mTR KO ).
Cardiac dilation and premature death in G2 animals
DMD is characterized by a progressive dilated cardiomyopathy with left ventricular wall thinning and increased diameter 22 . Analysis of hearts from young (8-and 20-week-old) mdx/mTR G2 (G2) mice revealed no obvious abnormalities in cardiac morphology (data not shown); however, by 32 weeks, increased left ventricle enlargement was evident in G2 hearts ( Fig. 1a,b ) relative to controls. Histologic and morphometric analysis of 32-week-old G2 hearts revealed extensive ventricular fibrosis (Fig. 1b ,c) in agreement with reports that extensive fibrosis and scarring, generally localized to the wall of the left ventricle, are the most prevalent cardiac histological features in end-stage DMD patients 22 . Heart-to-body weight and heart-to-tibia length ratio measurements revealed minimal compensatory hypertrophy in G2 animals ( Supplementary Fig. S1b ), consistent with the human disease. Cardiomyocyte nuclear area was moderately reduced in G2 hearts ( Supplementary Fig. S1d and e) and the cardiomyocyte diameter of G2 hearts was smaller than controls ( Supplementary Fig. S1d and f). Organ-to-body weight ratios for other organs (lungs, testis, liver, spleen) were unaffected ( Supplementary Fig. S1c ). These data show that the dilated cardiomyopathy seen in G2 hearts is not due to a systemic effect associated with premature ageing and severe functional and anatomic deficits in multiple organs.
Kaplan-Meier survival analysis demonstrated that the lifespan of mdx/mTR KO mice is significantly reduced when compared with controls ( Fig. 1d ). Death first occurs at 30 weeks with a t 50 of 120 weeks in G1 mice and as early as 19 weeks of age with a t 50 of 80 weeks of age in G2 mice. In contrast, controls including WT, Het and mTR G2 , demonstrated a normal lifespan ( Fig. 1d ). Together, these data indicate that dystrophin deficiency in combination with critically shortened telomeres recapitulates the features of dilated cardiomyopathy and reduced lifespan seen in patients with DMD (ref. 22) .
Cardiac dysfunction in G2 animals
To assess cardiac function, echocardiography was performed. Left ventricular contractility of G2 mice, measured as the percentage of fractional shortening, was progressively impaired as a function of age. Echocardiograms for control and G2 mice showed no significant differences at 12 weeks ( Supplementary Fig. S2a ) and 20 weeks of age ( Supplementary Fig. S2b ), but by 32 weeks, G2 mice exhibited a significant reduction in fractional shortening relative to controls (32 ± 5% versus 55 ± 3%, respectively; Supplementary Fig. S2a and Videos S1). Two measurements of left ventricular size showed chamber dilation in G2 mice. Left ventricular transverse area in diastole was moderately increased in G2 mice relative to controls (14 ± 2 mm 2 versus 8 ± 2 mm 2 , respectively). Left ventricular transverse area in systole was also increased (12 ± 2 mm 2 versus 4 ± 2 mm 2 , respectively; Fig. 2a,b ). Together these data show that cardiac contractile function is impaired and left ventricular chamber size is increased in G2 hearts. In addition, markers of cardiac failure, including atrial natriuretic shows that G2 mice have a significantly reduced lifespan when compared with controls. WT (n = 72), Het (n = 86), G1 (n = 45), G2 (n = 53) and mTR G2 (n = 45). Source data are shown in Supplementary  Table S1 . peptide (Anp) and brain natriuretic peptide (Bnp), were significantly elevated in G2 mice when compared with controls at 32 weeks ( Fig. 2c ), confirming progression to heart failure. Moreover, in response to stress (angiotensin II infusion), cardiac dysfunction was induced in younger G2 mice ( Supplementary Fig. S3 ). Notably, although at 32 weeks, G1 mice have normal cardiac function ( Fig. 2b ), older G1 mice (80 weeks) have significantly reduced cardiac function (fractional shortening, left ventricular transverse area in diastole and left ventricular transverse area in systole) relative to controls ( Supplementary Fig. S2c ). In accordance, mdx/mTR mice at G3 (8 weeks) exhibit similar cardiac dysfunction much earlier than mdx/mTR mice at G2 (32 weeks; Supplementary  Fig. S2c ), indicating that telomere shortening plays an integral role in the cardiac functional defects. Electrocardiograms (ECGs), a measure of cardiac electrical conduction, revealed delayed conduction in both G1 and G2 mice, evidenced by a wide QRS interval when compared with controls ( Fig. 2d ), indicating a significant ventricular depolarization defect in mdx/mTR KO hearts, consistent with findings seen in DMD patients 23 .
In contrast, age-matched WT, Het and mTR G2 control mice had normal QRS durations ( Fig. 2d ), providing further evidence that the observed electrical dysfunction results from the combined impact of dystrophin and telomere dysfunction.
Magnetic resonance imaging (MRI) provides dynamic visualization of systolic myocardial wall thickening, and the extent of relaxation and contraction in diastole and systole, respectively 24 . The results of MRI analyses were in accordance with the data obtained by echocardiography and showed that G2 mice exhibit reduced left ventricular systolic function ( Fig. 2e ). Together, the impaired contractile function, detected by echocardiography and MRI, the prolonged depolarization evident by ECG, the increase in heart failure markers, and early mortality indicate that the hearts of G2 mice become progressively dysfunctional.
Reduction in cardiomyocyte telomere length in G2 mice
To verify that cells within the hearts of G2 mice had shortened telomeres, we used a highly sensitive method for determining telomere Supplementary Table S1 .
length in tissue sections, telomere quantitative fluorescence in situ hybridization (telomere Q-FISH). This method has been used to obtain quantitative telomere length measurements both in murine 25, 26 and human cells [27] [28] [29] . We optimized fixation methods that enabled telomere Q-FISH to measure telomere length in combination with immunostaining of a marker of cardiomyocytes (cardiac troponin T; Fig. 3a and Supplementary Fig. S4a ). A highly significant 50% reduction in telomere length was evident in G2 cardiomyocytes relative to control (WT, Het) and G1 cardiomyocytes (Fig. 3b ). In contrast, control mTR at generation 2 (mTR G2 -lacking only TERC) cardiomyocytes exhibited a moderate reduction in telomere lengths, in agreement with studies by others 30, 31 , which do not report significant shortening until generations 4 and 5, demonstrating that the dystrophin mutation exacerbates telomere attrition.
To address whether telomere dysfunction in the smooth muscle of cardiac vessels contributes to the cardiac phenotype, we performed Supplementary Table S1 .
telomere Q-FISH in combination with immunostaining of a marker of vascular smooth muscle, α-smooth muscle actin ( Supplementary  Fig. S4b ,c). No significant differences in telomere lengths were evident in vascular smooth muscle cells of the different genotypes ( Supplementary Fig. S4b ,c). The standard control for Q-FISH was performed on testis ( Supplementary Fig. S4d ), as cell proliferation is ongoing in this tissue and it is the first to show a reduction in telomere lengths or weight. In all genotypes (including mdx/mTR G2 and mTR G2 ), no significant differences were seen in telomere lengths ( Supplementary  Fig. S4e ), tissue morphology 17 or organ weight ( Supplementary  Fig. S1c ), indicating that global telomere shortening is not the basis for the observed phenotype. These data highlight that the enhanced telomere shortening is specific to cardiac (not smooth) muscle cells in the heart, and is not a systemic effect.
Reduction in human cardiomyocyte telomere length in DMD hearts
To determine whether our findings in the mouse model were relevant to human DMD, we analysed post-mortem (<24 h) cardiac tissues from 4 DMD patients (13-, 15-, 17-and 19-year-old males). Telomere Q-FISH was performed in paraffin sections to assess telomere length in combination with immunostaining for the cardiac marker troponin T and nuclear DAPI stain ( Fig. 4a and Supplementary Fig. S4f ). Telomere lengths in human DMD cardiomyocytes were significantly reduced by 45%, (P < 0.005) when compared with cardiomyocytes from three post-mortem control hearts (20-, 25-and 30-year-old males without cardiac disease; Fig. 4b ). Similar to what is seen in the mdx/mTR mouse model, telomere Q-FISH combined with α-smooth muscle actin immunostaining ( Supplementary Fig. S4g ,h) demonstrated no significant difference in telomere length in the smooth muscle cells of cardiac vessels. These data validate the mdx/mTR KO mouse as a biologically relevant model of human DMD and provide evidence that telomere shortening in DMD patients is specific to cardiomyocytes.
Telomere dysfunction combined with dystrophin mutation induces mitochondrial dysfunction and induces oxidative stress
Although increased cardiomyocyte proliferation or apoptosis did not account for the observed cardiac dysfunction ( Supplementary Fig. S5 ), we observed profound mitochondrial aberrations. Mitochondrial compromise [31] [32] [33] and oxidative stress [34] [35] [36] [37] have previously been implicated in myocardial dysfunction. Moreover, a strong link between telomere dysfunction and impairment of mitochondrial ultrastructure and organ function, indicative of ageing, was shown for liver and heart in mice lacking telomerase only at late generations (for example, G4; ref. 30) . We therefore investigated the hypothesis that the dilated cardiomyopathy in mice at early generations (for example, G2) lacking telomerase and dystrophin is associated with mitochondrial dysfunction and oxidative stress. To assess whether telomere shortening in cardiomyocytes induces mitochondrial abnormalities in G2 mice, we performed electron microscopic analysis. Hearts from G2 animals exhibited multifocal abnormalities including a loss of thick as well as thin myofilaments (Fig. 5a ), and a moderately increased number of mitochondria (data not shown) combined with decreased mitochondrial size ( Fig. 5b ). Most notably, the morphology of the mitochondria was highly aberrant, evident by the extensive fragmentation of mitochondria in G2 relative to control mice and lack of well-defined cristae (Fig. 5a,b ). Our data suggest that mitochondrial abnormalities are accelerated in G2 mice lacking both telomerase and dystrophin, and strongly correlate with the observed cardiac dysfunction leading to early cardiac failure.
To determine whether the mitochondrial aberrations evident in the hearts of G2 mice at 32 weeks of age were mediated by the Supplementary  Table S1 .
master mitochondrial regulators peroxisome proliferator activated receptor gamma co-activator 1 α (Pgc1α) and β (Pgc1β), we assayed their expression by quantitative real-time PCR (rtPCR). As expected, PGC1α and 1β levels were moderately diminished relative to control mTR KO mice lacking telomerase only at generation 2 (∼50%), in agreement with a previous report 30 . Notably, however, expression levels of PGC1α and 1β in G2 mice lacking both telomerase and dystrophin (mdx/mTR KO ) were profoundly reduced (∼80%; Fig. 5c ). These data indicate that the cardiac phenotype of mice lacking telomerase is exacerbated by the high metabolic demands of contraction in the absence of dystrophin.
To determine whether the mitochondrial compromise and dilated cardiomyopathy seen in G2 mice was accompanied by increased oxidative stress, we stained cardiac tissue sections for 8-hydroxydeoxyguanosine (8-OHdG), a marker of oxidative damage [38] [39] [40] . A significant increase in the number of 8-OHdG-positive nuclei was detected in G2 hearts when compared with controls ( Fig. 5d,e ), indicating that oxidative stress is increased in G2 hearts. In agreement with this finding, expression of superoxide dismutase 1 and 2 (Sod1 and Sod2), enzymes with an antioxidant function, were significantly decreased ( Fig. 5f ), providing further evidence of augmented oxidative stress in G2 hearts. Notably, mitochondrial function and oxidative stress are exacerbated by telomere dysfunction in combination with dystrophin mutation in G2 mice, leading to lethal cardiomyopathy.
Amelioration of cardiac dystrophic phenotype after antioxidant treatment
To determine whether oxidative stress plays a role in the pathogenesis of G2 hearts, we subjected mice to two different antioxidants. The first (butylated hydroxyanisole (BHA); ref. 38 ) was administrated in the diet, and the second (Mn(III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP), which specifically targets mitochondria 41 ) was injected intraperitoneally daily ( Fig. 6a ). G2 mice treated with either antioxidant exhibited prolonged survival ( Fig. 6b,e ) and substantial amelioration of left ventricular function by echocardiography (fractional shortening; Fig. 6c ,f and Supplementary Fig. S6d ) relative to untreated G2 mice. MnTBAP was more potent than BHA by all functional measures and exhibited a reduction in fibrotic tissue and heart weight ( Supplementary Fig. S6a,b,c) . Moreover, transmission electron micrographs of longitudinal cardiac sections revealed improved mitochondrial cristae and morphology in MnTBAP-treated hearts when compared with saline-treated G2 controls (Fig. 6d ). Together, these findings demonstrate that administration of antioxidants ameliorates both morphological and functional defects and significantly delays the progression of dilated cardiomyopathy in mdx/mTR KO mice. These results suggest that the oxidative stress generated in the dystrophic heart is likely to play a causal role in cardiac dysfunction and is a potential early target for treatment in DMD patients.
DISCUSSION
Patients with DMD typically die from cardiorespiratory failure, yet most therapeutic strategies in development at present target the skeletal muscles. Although generally diagnosed on the basis of skeletal myopathic symptoms, the cardiac defect warrants attention and early intervention. Fifty per cent of DMD patients 6-10 years of age exhibit abnormal ECGs (ref. 23 ) and by mid-to late-teenage years Supplementary Table S1 .
progressive cardiac dysfunction is common [4] [5] [6] [7] 23 . Hearts from DMD patients are often characterized by multifocal areas of degenerative changes, characterized by mitochondrial disorganization with loss or discontinuity of cristae, fatty infiltration and loss of myofibres 23, 42 . Virtually all DMD patients develop dilated cardiomyopathy and cardiac arrhythmia by the end of their lives 7 . As DMD patients now Supplementary  Table S1 .
survive longer owing to increased options for supportive care 7, 43 , early treatments to prevent or limit the progressive dilated cardiomyopathy, which is now the leading cause of death, are highly desirable. However, the absence of a mouse model of DMD that faithfully mimics the pathophysiology of the human cardiomyopathy has limited our understanding of the underlying mechanisms and ability to test cardiac-specific therapies. The development of a mouse model that recapitulates lethal human DMD has been hindered for decades, as mdx mice (dystrophin deficiency alone) have a surprisingly mild phenotype. A number of more severe dystrophic phenotypes have been created by breeding the mdx mouse with mice in which utrophin 44 , MyoD (ref. 45 ), α 7 integrin (ref. 46 ), α-dystrobrevin 47 or glycan processing 48 has been knocked out. These other mouse models have been instructive and highly useful in augmenting our knowledge of muscle development and pathophysiology, as well as serving as useful test systems for therapeutic interventions. However, these models [44] [45] [46] [47] disrupt proteins essential for skeletal and/or cardiac muscle function that are not mutated or lost in DMD patients. An advantage of the mdx/mTR KO mouse model described here is that lack of dystrophin is coupled with shortened telomeres, as seen in humans with DMD. Mouse models that mimic other human genetic degenerative diseases 49, 50 associated with DNA repair (ataxia telangiectasia) were first generated when bred with mice with shortened telomeres. Here we show that the mdx mouse manifests all of the main hallmarks of human DMD once bred with mice that lack telomerase (mTR) yielding mdx mice with shortened telomeres (mdx/mTR KO ).
This report provides the first evidence for a cardiac phenotype in a mouse model of DMD and a conceptual basis for the disease mechanism. We previously reported that combined dystrophin and telomerase deficiency leads to a skeletal myopathy similar to that observed in human DMD, due to a chronic cycle of myofibre damage and repair that ultimately led to a loss of the stem cell reservoir due to the shortened telomeres 17, 51 . Here we show that this model manifests essentially all features of cardiomyopathy described in DMD patients 7, 22, 52 , including cardiac dilation, prolonged ventricular depolarization and decreased systolic function. We report ultrastructural changes in mitochondria, mitochondrial dysfunction including decreased levels of peroxisome proliferator-activated receptor γ and co-activator 1 α and β (Pgc1α and 1β), and markers of oxidative compromise (decreased Sod and increased 8-OHdG) in mdx/mTR KO mice. Although these changes are typically associated with cardiomyopathy and heart failure of diverse etiologies 53, 54 and shortened telomeres have also been detected in the hearts of patients with heart failure 55 , this is the first report showing that these features can result from progressive telomere erosion, specifically in cardiomyocytes owing to the genetic absence of a single crucial cardiac-specific gene product. Notably, telomere shortening was not detected in other muscle cells of the heart, such as those of the vasculature, providing further support for the specificity of telomere dysfunction in cardiomyocytes in the etiology of the disease. These defects culminate in dilated cardiomyopathy and heart failure with an onset of death by 19 and 32 weeks of age, in G1 and G2, respectively. The importance of telomere shortening in the etiology of dilated cardiomyopathy is underscored by our finding of shortened telomeres (45%) in the cardiomyocytes in four DMD patients (which lack dystrophin) when compared with controls (which express dystrophin).
Our data suggest that oxidative stress is a critical step in the pathogenesis of cardiac failure in patients with muscular dystrophy because antioxidants can ameliorate the main features of dilated cardiomyopathy and improve lifespan in our model. Moreover, although respiratory and skeletal muscle failure probably contribute to the observed cardiac phenotype, our findings highlight an intrinsic cardiac defect. On the basis of our results, we postulate that the mdx/mTR G2 mouse model sets in motion a cycle whereby stress is initiated by the absence of dystrophin during continuous cycles of cardiac contraction in conjunction with short telomeres (already shortened in humans), which induces mitochondrial compromise and increased oxidative stress, which then leads to further telomere erosion and progression to lethal dilated cardiomyopathy. We postulate that as in DMD, shortened telomeres may well exacerbate other heritable tissue-specific protein deficits, as the long telomeres typical of mice may mask their manifestation. The findings reported here increase our understanding of DMD and will facilitate the development and testing of therapies targeted to treat or prevent the onset of heart failure and death.
METHODS
Methods and any associated references are available in the online version of the paper. 20 and C57BL6 mTR Het mice 19 were used to generate the double-mutant animals as described in Supplementary Fig. S1a . Genotyping was performed by PCR as described previously 17 . As the human disease is X-linked 21 , our studies were restricted to male mice. The exact number of animals for each data set and all relevant details regarding the sample size are reported with each experiment. ECG analysis. ECGs were recorded to assess intra-left-ventricle conduction using Chart for Windows v4.1 (AD Instruments, Colorado Springs) as described previously 56 . ECGs were recorded from needle electrodes inserted subcutaneously in the chest and secured with tape. If the ECG was abnormal, other positions were used to validate and/or further characterize the ECG abnormality. The signal was acquired for 1 min and in three different electrode chest positions per mouse. During offline analysis, we examined the 1 min recording for unusually shaped QRS and for time-varying phenomenon (for example, irregularities in interval durations). Ectopic or abnormal beats were noted. A representative 10-15 s segment of the recording was averaged to obtain the signal averaged ECG.
Echocardiographic analysis. Animals were anaesthetized with isoflurane (1.5% in O 2 ) and the left hemithorax was shaved. The mice were placed on a temperaturecontrolled pad and heart rate was continuously monitored (400-550 bpm). Ultrasound transmission gel (Parker Laboratories) was used and the heart was imaged in the parasternal short-axis view. Two-dimensional B-mode and M-mode images were obtained at the papillary muscle level using the Vevo 770 Ultrasound system (VisualSonics) and left ventricular transverse area in systole, left ventricular transverse area in diastole and fractional shortening were calculated using the using Vevo 770 V2.2.3 software (VisualSonics). All analyses were performed with the investigators blinded to genotype.
Magnetic resonance imaging analysis. Magnetic resonance imaging was performed at the Stanford Clark Center Small Animal Imaging Facility in a self-shielded Varian/General Electric microSigna 7.0 7T, 310 mm (horizontal) bore scanner (Varian, GE Healthcare), including Copley gradient drivers, EXCITE2 electronics, the supporting LX11 platform, and a custom-built quadrature birdcage radiofrequency coil. Animals were anaesthetized with 2% isoflurane in humidified medical-grade oxygen. Physiological respiration and temperature feedback was carefully monitored and cardiac acquisitions were gated to the cardiac cycle. The animal was placed on an animal bed while kept under anaesthesia. During the scan, the heart rate, respiration and ECG signals were monitored closely. Transverse cardiac images were acquired with a fast gradient echo sequence, a flip angle of 20 • , repetition time of 200 ms, echo time of 0.9 ms, slice thickness of 1 mm, 3 cm field of view with a 256 × 256 matrix, and a number of excitations (averages) of 2. Image analysis was performed using the open source software Osirix (http://www.osirixviewer.com).
Electron microscopy. Samples were fixed in Karnovsky's fixative (2% glutaraldehyde (EMS) and 4% paraformaldehyde (EMS) in 0.1 M sodium cacodylate (EMS) at pH 7.4) for 1 h at room temperature, then cut, post-fixed in 1% osmium tetroxide (EMS) for 1 h at room temperature, washed 3 times with ultrafiltered water, and then en bloc stained for 2 h at room temperature or moved to 4 • C overnight. Samples were then dehydrated in a series of ethanol, followed by acetonitrile for 15 min. Samples were infiltrated with EMbed-812 resin (EMS) mixed 1:1 with acetonitrile for 2 h followed by 2 parts EMbed-812 to 1 part acetonitrile for 2 h. The samples were then placed into EMbed-812 for 2 h, then placed into moulds (and resin-filled gelatin capsules with labels were orientated properly) and placed into a 65 • C oven overnight. Sections were taken between 75 and 90 nm on a Leica Ultracut S (Leica) and grids were contrast stained for 15 min in 1:1 saturated UrAcetate (∼7.7%) to 100% ethanol followed by staining in 0.2% lead citrate for 3 min. Photos were taken using a Gatan Orius digital camera.
Chronic angiotensin administration. Osmotic minipumps (Alzet 2004) filled
either with angiotensin II (0.9 µg h −1 , Sigma A9525) or 0.9% saline were implanted subcutaneously into each mouse, as described previously 57 .
Cardiac morphology and morphometric analysis. Hearts were excised at the indicated ages and fixed overnight in 4% paraformaldehyde. Following progressive tissue dehydration with ethanol and xylene, the heart samples were embedded in paraffin. Cross-sections (7 µm thick) were subjected to trichrome staining (Sigma-Aldrich) for nuclei, cytoplasm and collagen visualization. Images from randomly chosen fields distributed across the cardiac section were collected using a Zeiss stage microscope (AxionVision) and morphometric analysis for collagen tissue deposition was performed with MetaMorph software (version 6.2r5; Universal Imaging).
Quantitative-rtPCR-based gene expression analysis.
Total RNA was isolated from hearts using TRIzol (Invitrogen). RNA was treated with DNaseI enzyme (Promega) for 1 h at 37 • C and then subjected to column purification (Qiagen). The RNA concentration was determined with a spectrophotometer. After RNA quality verification, 1 µg was used to prepare cDNA (Ready-To-Go, T-Primed First-Strand Kit, Amersham Bioscience 27-9263-01). Inventoried TaqMan FAM probes (Applied Biosystems) were used for the relative quantification of the mRNA levels of atrial natriuretic peptide (Anp) (Mm01255747 g 1), brain natriuretic peptide (Bnp) (Mm00435304 g 1), superoxide dismutase (Sod1) (Mm01344232 g 1) and Sod2 (Mm00449726 m 1), peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgc1α) (Mm00447184 g 1) and 1-β (Pgc1β) (Mm01258517 g 1) genes. Taqman VIC glyceraldehyde 3-phosphate dehydrogenase (Gapdh) probes (4552339E) were used for normalization. Data analysis was performed using the C(T ) method.
Immunofluorescence microscopy. Slides were deparaffinized in xylene and rehydrated in serial ethanol concentrations. Antigen masking was performed in citrate buffer (10 mmol l −1 sodium citrate, pH 6.0) for 30 min in a pressure cooker. Slides were blocked with 5% normal goat serum (DAKO) for 1 h at room temperature. Telomere Q-FISH. Sections (4 µM thick) of embedded paraffin hearts were cut and preheated to 65 • C for 10 min and passed through xylene to remove paraffin. Slides were hydrated through a graded ethanol series, deionized water and then immersed for 60 s in dH 2 O with 1% Tween-20 detergent, followed by immersion in citrate buffer at pH 6.0 in a steamer for 35 min. After cooling, slides were immersed in dH 2 O, 70% ethanol and 95% ethanol, and then allowed to dry at room temperature. Thirty-five microlitres of diluted PNA probe hybridization solution (0.3 µg ml −1 Cy3-labelled telomere PNA and 0.3 µg ml −1 FITC-labelled centromere PNA; both probes custom synthesized by Bio-Synthesis) was placed onto the specimen. After denaturation (84 • C, 5 min), slides were left overnight to hybridize (dark). Next, slides were washed twice with PNA wash solution (formamide, 1 M Tris at pH 7.5 and dH 2 O) and PBST, and were blocked for 1 h with blocking solution (Invitrogen). Afterwards, slides were incubated for 1 h at room temperature with primary antibodies (anti-mouse α-cardiac troponin T (1:100, Abcam) or anti-rabbit α-smooth muscle (1:100, Abcam)), washed with PBST, incubated with secondary antibodies (anti-mouse IgG fraction Alexa Fluor 488 (Molecular Probes) or anti-rabbit IgG fraction Alexa Fluor 488 (Molecular Probes)) for 30 min, counterstained with 1 µg ml −1 DAPI solution in dH 2 O, washed DOI: 10.1038/ncb2790 in dH 2 O, air dried and mounted (Prolong, Molecular Probes). To avoid differences in day-to-day staining efficiency variation, Q-FISH and immuno-Q-FISH staining as well as the image capture were performed on the same day. To control for differences in ploidy and probe accessibility, FITC-labelled PNA probes were used that recognize centromeric major satellite repeats, as described previously 28, 29 . DAPI staining was used to define nuclear area and for quantification of DNA content, and Cy3 staining was used to quantify telomere fluorescence. Telomere fluorescence signals for individual cells of interest were identified by overlay of the DAPI image. Omega Optical XF38 filter set (Omega Optical Incorporated) for Cy3 visualization was used as described in ref. 29 . The range of focal planes was examined on the Z axis to determine that cardiomyocyte nuclei were within the striated muscle. Images were acquired at ×40. The investigators were blinded to the genotype of the sections analysed. Data were analysed using the Telometer: Software for Telomere Counting as described previously at http://demarzolab.pathology.jhmi.edu/telometer/. The algorithm developed at Johns Hopkins performs subtraction of background noise of the entire image, distinction of the individual telomere spots, removal of halos and separation of conjoined telomeres. The program generated statistics on the entire region of the nucleus, as well as each individual telomere in the nucleus. Statistics returned include the intensity sum of all Cy3 telomere pixels for a given nucleus (proportional to telomere length) and the intensity sum of all DAPI pixels for the nucleus (proportional to total nuclear DNA content). By taking the ratio of the telomere intensity sum to the corresponding DAPI intensity sum one is able to compensate for ploidy differences as well as the variable fractions of nuclei present in the cutting plane of the tissue section.
Antioxidant treatments. The commonly used 2018 Global diet (Mucedola srl) was used as normal diet, whereas the antioxidant diet was the same 2018 Global diet only supplemented with 0.7% of the antioxidant compound butylated hydroxyanisole (BHA; Sigma). Both normal and antioxidant food were weighed every day to ensure similar food intake in all of the experimental groups of the animals. In a second experiment using the alternative antioxidant Mn(III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP), mice were treated every day until 42 weeks of age with 10 mg kg −1 ) MnTBAP intraperitoneally or saline vehicle. Antioxidant treatments were provided at 8 weeks of age and onwards. Animals were kept in single cages to correlate food reduction in the cage with caloric intake for each mouse. Water was provided daily in graduated bottles to monitor liquid reduction. Detailed monitoring of cardiac function by echocardiography was performed before and monthly during the antioxidant treatments. The experiment was terminated between 40 and 42 weeks of age and the hearts were examined at the histological and molecular level. For each treatment, at least 10 animals were tested per genotype and condition.
Statistical analysis. Values were expressed as mean ± s.e.m. and differences with P value <0.05 were considered significant ( * P < 0.05, * * P < 0.01, * * * P < 0.001). Comparisons between two groups were performed using Student's t -test (tail 2, type 2 or 3). Repeated measures experiments were analysed by analysis of variance followed by Bonferonni's post-hoc corrections. All statistical analyses were performed using Excel or GraphPad Prism software. Source data are shown in Supplementary Table S1 . 
